164223-35-2

Upstream product

• 1071-46-1 hydrogen ethyl malonate 
• 875932-90-4 (3-imidazol-1-yl-3-oxo-propyl)-carbamic acid benzyl ester 
• 2304-94-1 3-(benzyloxycarbonylamino)propanoic acid 
• 6148-64-7 ethyl potassium malonate 
• 1246303-67-2 [3-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-yl)-3-oxo-propyl]-carbamic acid benzyl ester 

Downstream Products

• 505031-91-4 (E)-5-Benzyloxycarbonylamino-3-pyrrolidin-1-yl-pent-2-enoic acid ethyl ester 
• 182247-94-5 ethyl (3R)-5-benzyloxycarbonylamino-3-hydroxypentanoate 
• 1454302-74-9 4-(2-amino-ethyl)-2-phenoxymethyl-oxazole-5-carboxylic acid ethyl ester 
• 1454302-81-8 5-(4-fluoro-phenyl)-2-phenoxymethyl-6,7-dihydro-5h-oxazolo [5,4-c]pyridin-4-one 
• 1454303-02-6 5-(5-fluoro-4-methoxy-pyrimidin-2-yl)-2-phenoxymethyl-6,7-dihydro-5H-oxazolo [5,4-c]pyridin-4-one 
• 1454303-09-3 2-phenoxymethyl-6,7-dihydro-5H-oxazolo[5,4-c]pyridin-4-one 
• 1454303-13-9 5-methyl-2-phenoxymethyl-6,7-dihydro-5H-oxazolo[5,4-c]pyridin-4-one 
• 1454302-65-8 5-benzyloxycarbonylamino-2-chloro-3-oxo-pentanoic acid ethyl ester 
• 1454302-66-9 5-benzyloxycarbonylamino-3-oxo-2-(2-phenoxy-acetoxy)-pentanoic acid ethyl ester 
• 1234064-19-7 Mini₁₀₆ 
• 164223-36-3 Ethyl 5-(2-benzyloxycarbonylaminoethyl)-3-methylisoxazole-4-carboxylate 
• 226704-28-5 5-(2-Benzyloxycarbonylaminoethyl)-3-methylisoxazole-4-carboxylic acid 
• 164223-48-7 3,5,7-Trimethyl-7-phenylseleno-4,5,6,7-tetrahydroisoxazolo<4,5-c>pyridin-4-one 
• 164223-47-6 3,5-Dimethyl-7-phenylseleno-4,5,6,7-tetrahydroisoxazolo<4,5-c>pyridin-4-one 

Relevant academic research and scientific papers

CONDENSED LACTAM DERIVATIVE

The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.

BICYCLIC OXAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS

In one aspect, the invention relates to substituted bicyclic oxazole lactam analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES

Disclosed compounds of formula (I), which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Dihydropyrimidinones--a new class of anti-staphylococcal antibiotics.

We report the synthesis and pharmacological evaluation of new derivatives of natural dipeptide antibiotic TAN-1057 A, B. In the course of this program, we identified novel analogues of the natural product that display similar antibacterial activity and showed improved tolerability.

1,3-Dipolar cycloaddition route to nitrogen heterocyclic triones

1,3-Dipolar cycloaddition of nitrile oxides, formed in situ by dehydration of primary nitro compounds, with pyrrolidine enamines of protected γ- or δ-amino-β-keto esters affords isoxazole-4-carboxylates; these undergo lactam formation and N-O bond cleavage to afford 3-acyltetramic acids and 3-acyl-4-hydroxypyridin-2-ones.

N-substituted-7-amino-5-hydroxy-3-oxoheptanoic acid derivatives and method for producing the same

Compounds represented by the following general structural formula (1) and methods for producing the compounds: STR1 R1 represents a group such as benzyloxycarbonyl, R2 represents a lower alkyl group, R3 represents a hydrogen atom or a protecting group, each of M1 and M2 represents a metal atom, and n represents the atomic valence of M1. Intermediates for HMG-CoA reductase inhibitors can be prepared safely and easily from these compounds.